 "Kiran Mazumdar-Shaw")
Biocon has signed with Sandoz, the generics arm of the $48.52-billion Swiss Pharma giant Novartis to jointly invest and co-develop, manufacture and market, a new range of biosimilars in immunology and cancer for the global market.
Both firms will have an equal share in the development of biosimilars — a drug that is similar to an existing biological drug and that needs to be approved for safety, purity, and potency by regulators; manufacture and have cost and profit share business model. While Sandoz will take the product commercially in the regulated US and Europe markets, Biocon will have rights to
